
Tracon Pharmaceuticals shares update on ENVASARC phase 2 trial
Betsy Goodfellow | December 21, 2023 | News story | Research and Development | ENVASARC, Pharmacy, Tracon Pharmaceuticals, clinical trial
Tracon Pharmaceuticals has shared an update from the ongoing phase 2 ENVASARC trial, which has now enrolled more than 70 of the 80 planned patients for Cohort C of the single agent envafolimab treatment at a 600mg dose every three weeks.
As well as the enrolment figures, the company shared additional safety and efficacy data which has ben reviewed for 46 patients. At the time of the analysis, patients had completed a minimum of 12 weeks of efficacy evaluations which saw an objective response rate of 13% by investigator review and 8.7% by blinded independent central review (BICR).
The median duration of response by BICR is currently over six months, and the drug has been seen to be well tolerated.
Further safety and efficacy data are expected in the first quarter of 2024.
Charles Theuer MD PhD, Tracon Pharmaceuticals’ chief executive officer, commented: “We continue to believe that these data position envafolimab to become a potentially compelling treatment option for patients with the refractory sarcoma subtypes of UPS and MFS based on the ORR and tolerability data to date. ENVASARC enrollment continues to be brisk, reflecting the high unmet need that exists for these patients.”
Betsy Goodfellow
Related Content

Tridem begins phase Ib trial of Parkinson’s disease vaccine
Tridem Bioscience has enrolled the first patients in a phase Ib clinical trial of TRB-001, …

How will biomarker-led diagnostics reshape respiratory medicine?
By Dr Louise Ryan Murphy, Chronic obstructive pulmonary disease (COPD) is typically diagnosed and assessed …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis
UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …





